Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cyclacel Pharmaceuti (CYCCP)

Cyclacel Pharmaceuti (CYCCP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 420 K
  • Annual Income, $ -22,555 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.20 +16.35%
on 12/12/24
6.98 -13.32%
on 12/04/24
-0.89 (-12.82%)
since 11/19/24
3-Month
5.20 +16.35%
on 12/12/24
8.00 -24.37%
on 10/18/24
-0.95 (-13.57%)
since 09/18/24
52-Week
5.20 +16.35%
on 12/12/24
22.20 -72.75%
on 02/01/24
-7.85 (-56.47%)
since 12/19/23

Most Recent Stories

More News
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

 - Oral fadraciclib demonstrated good tolerability with continuous dosing; anticipate entering Phase 2 POC stage in 2H 2022 –          - Demonstrated...

CYCC : 0.3174 (-4.11%)
CYCCP : 6.05 (+8.42%)
Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a...

CYCC : 0.3174 (-4.11%)
CYCCP : 6.05 (+8.42%)
Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline

- Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors - - No Dose Limiting Toxicities Observed at All Dose Levels...

CYCC : 0.3174 (-4.11%)
CYCCP : 6.05 (+8.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

CYCCP Dividends

Date Value
07/15/15 $0.1500
04/15/15 $0.1500
12/31/14 $0.1500
09/29/14 $0.1500
06/27/14 $0.1500
04/15/14 $0.1500
01/15/14 $0.1500
10/17/13 $0.1500
07/18/13 $0.1500
04/17/13 $0.1500
01/17/13 $0.1500
04/19/11 $0.1500
01/19/11 $0.1500
01/14/09 $0.1500
10/16/08 $0.1500
07/16/08 $0.1500
04/16/08 $0.1500
01/16/08 $0.1500
10/17/07 $0.1500
07/18/07 $0.1500
04/18/07 $0.1500
01/18/07 $0.1500
10/19/06 $0.1500
07/20/06 $0.1500
04/26/06 $0.1500
01/18/06 $0.1500
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar